

## Separation of Zolmitriptan and its Organic Impurities per USP Monograph

Trivikram Reddy Gundala<sup>1</sup>, Krishna Chaitanya Routhu<sup>1</sup>, Swetha Kotikalaupdi<sup>1</sup>, and Bryan Tackett, PhD<sup>2</sup>

<sup>1</sup>India PhenoLogix, Mahadeva Kodigehalli, Hobli, Jala Taluka, Bengaluru 562149, India

<sup>2</sup>Phenomenex Inc., 411 Madrid Ave., Torrance, CA 90501, USA

### Overview

Zolmitriptan is a selective serotonin receptor agonist of the 1B and 1D subtypes and its action on 5-HT 1B/1D receptors causes vasoconstriction in intracranial blood vessels. The development of a quick and efficient analysis of Zolmitriptan and its related organic impurities is of interest for generic drug manufacturers. In this application note, we report on the separation of Zolmitriptan and its related organic impurities using three batches of Luna Omega 5 µm C18 columns according to the USP monograph for Zolmitriptan.

The use of the 150 mm length Luna Omega 5 µm C18 column is an allowable adjustment per USP <621> since the L/dp ratio (150/5 = 30,000) is within the allowable range of -25 to +50 % of the L/dp ratio (125/5 = 25,000) for the original 125 mm length, 5 µm column used to elucidate the assay method.

System suitability per USP Monograph for the Zolmitriptan Assay requires resolution no less than (NLT) 5.0 between Zolmitriptan and Zolmitriptan Related Compound E, a percent relative standard deviation (%RSD) of no more than (NMT) 0.73 % for Zolmitriptan, and a symmetry factor NMT 2.0 for Zolmitriptan. All system suitability requirements for Zolmitriptan Assay were met with all three batches of Luna Omega C18 columns (**Figure 2**).

System suitability per USP Monograph for the Zolmitriptan Organic Impurities requires resolution NLT 5.0 between Zolmitriptan and Zolmitriptan Related Compound E and a symmetry factor NMT 3.0 for Zolmitriptan. These requirements for system suitability for Organic Impurities were met with all three batches of Luna Omega C18 columns (**Figure 3**).

Across the three batches of Luna Omega C18 columns tested, the retention time reproducibility for Assay was 1.33 % and 1.79 % for Zolmitriptan and Related Compound E, respectively (**Table 2**).

All solutions were prepared as indicated in the USP Monograph for Zolmitriptan. USP Zolmitriptan RS (Catalog No. 1727009) and USP Zolmitriptan Related Compound E RS (Catalog No. 1727064) were purchased from USP.

### LC-UV Conditions

**Column:** Luna™ Omega 5 µm C18

**Dimensions:** 150 X 4.6 mm

**Part No.:** [00F-4785-E0](#)

**Mobile Phase:** **Mobile Phase (Table 1)**

**Flow Rate:** 1 mL/min

**Injection Volume:** 20 µL

**Temperature:** Ambient

**Detector:** UV @ 225 nm

**System:** Waters® Arc HPLC

**Table 1.** Preparation of Solutions

Solution	Composition
<b>Mobile Phase</b>	Acetonitrile / Water / Trifluoroacetic Acid / Triethylamine (135:865:1:0.25, v/v/v/v)
<b>Diluent</b>	<b>Mobile Phase</b>
<b>Standard Solution – Assay</b>	0.025 mg/mL of USP Zolmitriptan RS in <b>Diluent</b>
<b>System Suitability Solution – Assay</b>	0.12 µg/mL of USP Zolmitriptan Related Compound E RS and 25 µg/mL of USP Zolmitriptan RS in <b>Diluent</b>
<b>System Suitability Solution – Organic Impurities</b>	0.5 µg/mL of USP Zolmitriptan Related Compound E RS and 0.1 mg/mL of USP Zolmitriptan RS in <b>Diluent</b>

**Figure 1.** Zolmitriptan Structure







Figure 2. System Suitability Solution – Assay



Peak No.	Analyte	Retention Time (min)	Resolution	Area %RSD	Symmetry Factor
1	Zolmitriptan	7.22	11.18	0.04	1.10
2	Zolmitriptan Related Compound E	11.14		-	-
N = 6 Injections					




Peak No.	Analyte	Retention Time (min)	Resolution	Area %RSD	Symmetry Factor
1	Zolmitriptan	7.12	10.14	0.16	1.30
2	Zolmitriptan Related Compound E	10.91		-	-
N = 6 Injections					




Peak No.	Analyte	Retention Time (min)	Resolution	Area %RSD	Symmetry Factor
1	Zolmitriptan	7.03	10.65	0.27	1.06
2	Zolmitriptan Related Compound E	10.75		-	-
N = 6 Injections					



Figure 3. System Suitability Solution – Organic Impurities




Peak No.	Analyte	Retention Time (min)	Resolution	Symmetry Factor
1	Zolmitriptan	7.08	11.0	1.48
2	Zolmitriptan Related Compound E	11.03		-



Peak No.	Analyte	Retention Time (min)	Resolution	Symmetry Factor
1	Zolmitriptan	7.01	9.86	1.61
2	Zolmitriptan Related Compound E	10.87		-

N = 6 Injections



Peak No.	Analyte	Retention Time (min)	Resolution	Symmetry Factor
1	Zolmitriptan	6.90	10.64	1.41
2	Zolmitriptan Related Compound E	10.68		-

N = 6 Injections



**Table 2.** Batch-to-Batch Retention Time Reproducibility of Luna™ Omega 5 µm C18 Columns for Assay

Batch No.	Zolmitriptan	Zolmitriptan Related Compound E
1	7.22	11.14
2	7.12	10.91
3	7.03	10.75
<b>Mean</b>	<b>7.12</b>	<b>10.93</b>
<b>STD</b>	<b>0.10</b>	<b>0.20</b>
<b>%RSD</b>	<b>1.33</b>	<b>1.79</b>



**Need a different column size or sample preparation format?**

No problem! We have a majority of our available dimensions up on [www.phenomenex.com](http://www.phenomenex.com), but if you can't find what you need right away, our super helpful Technical Specialists can guide you to the solution via our online chat portal [www.phenomenex.com/Chat](http://www.phenomenex.com/Chat).

**Australia**

t: +61 (0)2-9428-6444  
auinfo@phenomenex.com

**Austria**

t: +43 (0)1-319-1301  
anfrage@phenomenex.com

**Belgium**

t: +32 (0)2 503 4015 (French)  
t: +32 (0)2 511 8666 (Dutch)  
beinfo@phenomenex.com

**Canada**

t: +1 (800) 543-3681  
info@phenomenex.com

**China**

t: +86 400-606-8099  
cninfo@phenomenex.com

**Czech Republic**

t: +420 272 017 077  
cz-info@phenomenex.com

**Denmark**

t: +45 4824 8048  
nordicinfo@phenomenex.com

**Finland**

t: +358 (0)9 4789 0063  
nordicinfo@phenomenex.com

**France**

t: +33 (0)1 30 09 21 10  
franceinfo@phenomenex.com

**Germany**

t: +49 (0)6021-58830-0  
anfrage@phenomenex.com

**Hong Kong**

t: +852 6012 8162  
hkinfo@phenomenex.com

**India**

t: +91 (0)40-3012 2400  
indiainfo@phenomenex.com

**Indonesia**

t: +62 21 5019 9707  
indoinfo@phenomenex.com

**Ireland**

t: +353 (0)1 247 5405  
eireinfo@phenomenex.com

**Italy**

t: +39 051 6327511  
italiainfo@phenomenex.com

**Japan**

t: +81 (0) 120-149-262  
jpinfo@phenomenex.com

**Luxembourg**

t: +31 (0)30-2418700  
nlinfo@phenomenex.com

**Mexico**

t: 01-800-844-5226  
tecnicomx@phenomenex.com

**The Netherlands**

t: +31 (0)30-2418700  
nlinfo@phenomenex.com

**New Zealand**

t: +64 (0)9-4780951  
nzinfo@phenomenex.com

**Norway**

t: +47 810 02 005  
nordicinfo@phenomenex.com

**Poland**

t: +48 22 104 21 72  
pl-info@phenomenex.com

**Portugal**

t: +351 221 450 488  
ptinfo@phenomenex.com

**Singapore**

t: +65 6559 4364  
sginfo@phenomenex.com

**Slovakia**

t: +420 272 017 077  
sk-info@phenomenex.com

**Spain**

t: +34 91-413-8613  
espinfo@phenomenex.com

**Sweden**

t: +46 (0)8 611 6950  
nordicinfo@phenomenex.com

**Switzerland**

t: +41 (0)61 692 20 20  
swissinfo@phenomenex.com

**Taiwan**

t: +886 (0) 0801-49-1246  
twinfo@phenomenex.com

**Thailand**

t: +66 (0) 2 566 0287  
thaiinfo@phenomenex.com

**United Kingdom**

t: +44 (0)1625-501367  
ukinfo@phenomenex.com

**USA**

t: +1 (310) 212-0555  
[www.phenomenex.com/chat](http://www.phenomenex.com/chat)

**🌐 All other countries/regions  
Corporate Office USA**

t: +1 (310) 212-0555  
[www.phenomenex.com/chat](http://www.phenomenex.com/chat)

**www.phenomenex.com**

Phenomenex products are available worldwide. For the distributor in your country/region, contact Phenomenex USA, International Department at [international@phenomenex.com](mailto:international@phenomenex.com)

**BE-HAPPY™**  
GUARANTEE

Your happiness is our mission. Take 45 days to try our products. If you are not happy, we'll make it right.

[www.phenomenex.com/behappy](http://www.phenomenex.com/behappy)

**Terms and Conditions**

Subject to Phenomenex Standard Terms and Conditions, which may be viewed at [www.phenomenex.com/TermsAndConditions](http://www.phenomenex.com/TermsAndConditions).

**Trademarks**

Luna and BE-HAPPY are trademarks of Phenomenex. Waters is a registered trademarks of Waters Technologies Corporation.

**Disclaimer**

Comparative separations may not be representative of all applications  
Phenomenex is in no way affiliated with Waters Technologies Corporation.

*FOR RESEARCH USE ONLY. Not for use in clinical diagnostic procedures.*

© 2022 Phenomenex, Inc. All rights reserved.

